Pay in 4 interest-free payments of $5.05 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
INTRODUCTION The recent and rapid rise of the GLP-1 receptor agonists semaglutide (Ozempic, Rybelsus and Wegovy) and tirzepatide (Mounjaro and Zepbound) offers a critical lens through which we can examine the intersection of financialization, patent abuse, and health inequities in the pharmaceutical industry
Disruption in microbiota homeostasis enhances the risk of metabolic conditions [83, 84]
As the use of therapeutic peptides such as GLP-1 agonists becomes more common, it is vital to ensure the quality, safety, and efficacy of products intended for use in patients
Eli Lilly is running a direct head-to-head trial comparing the two drugs (NCT06662383, 800 patients)
US$ 25.45
US$ 27.44
US$ 28.11
